Belimumab in childhood systemic lupus erythematosus: A review of available data
IntroductionChildhood systemic lupus erythematosus (cSLE) is a complex multisystem autoimmune disease. In 2019, belimumab was approved for the clinical treatment for cSLE, making it the only biological agent approved for cSLE children aged 5 and older in 60 years.ObjectiveTo review emerging evidence...
-д хадгалсан:
| Үндсэн зохиолчид: | , , , , , , |
|---|---|
| Формат: | Artigo |
| Хэл сонгох: | Inglês |
| Хэвлэсэн: |
Frontiers Media S.A.
2022-07-01
|
| Цуврал: | Frontiers in Immunology |
| Нөхцлүүд: | |
| Онлайн хандалт: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.940416/full |
| Шошгууд: |
Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!
|